

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A02/2016 OS WB

DISPATCHED ON 02ND FEBRUARY 2016

HLA PHENOTYPE OF BLOOD DONOR: HLA-A11,A31; B7, B60; Cw7, Cw10; DR4, -; DQ7, DQ8

| | | | Summary of Results | | | | | | | | |
|--------------------------|-----------------------|-------------------|--------------------|---------------------|-----------------|-----------------|---------------------|---------------------|----------|----------|--------------------|
| | | | PBL/T-Cells | | | | B-Cells | | | | |
| Total tested | 21 | 20 | 21 | 20 | 17 | 17 | 17 | 17 | | | |
| Positive | 1 | 1 | 1 | 0 | 0 | 14 | 5 | 0 | | | |
| Negative | 20 | 19 | 20 | 20 | 17 | 3 | 12 | 17 | | | |
| NT/Equivocal | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | | | |
| % Positive | 4.8% | 5.0% | 4.8% | 0.0% | 0.0% | 82.4% | 29.4% | 0.0% | | | |
| % Negative | 95.2% | 95.0% | 95.2% | 100.0% | 100.0% | 17.6% | 70.6% | 100.0% | | | |
| Consensus | Negative | Negative | Negative | Negative | Negative | Positive | Not Assessed | Negative | | | |
| HLA Antibody Specificity | DR17+ | Cw4, Cw6 | B14+ | B8,B44,DR5,DR8 DR13 | DR17+ | Cw4, Cw6 | B14+ | B8,B44,DR5,DR8 DR13 | | | |
| (Defined By CDC) | | | | | | | | | | | |
| | | | Without DTT | | | | Without DTT | | | | |
| Lab No. | PBL/T Cell Assessment | B Cell Assessment | Serum 1 | Serum 2 | Serum 3 | Serum 4 | Serum 1 | Serum 2 | Serum 3 | Serum 4 | Comments |
| 101 | YES | YES | Negative | Negative | Negative | Negative | Negative | Positive | Negative | Negative | |
| 114 | YES | YES | Negative | Negative | Negative | Negative | Negative | Positive | Negative | Negative | |
| 116 | YES | YES | Negative | Positive | Negative | Negative | Negative | Positive | Positive | Negative | |
| 117 | YES | NO | Negative | Negative | Negative | Negative | | | | | |
| 133 | YES | YES | Negative | Negative | Negative | Negative | Negative | Positive | Negative | Negative | |
| 136 | YES | NO | Negative | Negative | Positive | Negative | | | | | |
| 145 | YES | YES | Negative | Negative | Negative | Negative | Negative | Positive | Negative | Negative | |
| 149 | YES | NO | Negative | Negative | Negative | Negative | | | | | |
| 162 | YES | YES | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | |
| 163 | YES | YES | Negative | Negative | Negative | Negative | Negative | Positive | Negative | Negative | |
| 186 | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Positive | Negative | |
| 204 | YES | YES | Negative | Negative | Negative | Negative | Negative | Positive | Negative | Negative | |
| 206 | YES | YES | Negative | Negative | Negative | Negative | Negative | Positive | Negative | Negative | |
| 212 | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |
| 227 | YES | YES | Negative | Negative | Negative | Negative | Negative | Positive | Negative | Negative | |
| 235 | YES | NO | Positive | NT | Negative | NT | | | | | Low cell viability |
| 243 | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |
| 268 | YES | YES | Negative | Negative | Negative | Negative | Negative | Positive | Negative | Negative | |
| 284 | YES | YES | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | |
| 311 | YES | YES | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | |
| 315 | YES | YES | Negative | Negative | Negative | Negative | Negative | Positive | Negative | Negative | |

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A02/2016 OS WB

DISPATCHED ON 02ND FEBRUARY 2016

| Lab No. | PBL/T-cell without DTT | | | | B-cell without DTT | | | | Cell viability % | | |
|---------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|------------------|---------|---------|
| | Serum 1 reaction strength | Serum 2 reaction strength | Serum 3 reaction strength | Serum 4 reaction strength | Serum 1 reaction strength | Serum 2 reaction strength | Serum 3 reaction strength | Serum 4 reaction strength | PBL | T-cells | B-cells |
| 101 | 1 | 1 | 1 | 1 | 1 | 6 | 1 | 1 | | 100 | 100 |
| 114 | 1 | 1 | 1 | 1 | 1 | 6 | 1 | 1 | | | |
| 116 | 1 | 1-2 | 1 | 1 | 1 | 4-6 | 4 | 1-2 | | 95 | 85 |
| 117 | 1 | 1 | 1 | 1 | | | | | 70 | | |
| 133 | 0 | 0 | 0 | 0 | 0 | ++++ | 0 | 0 | | 80 | 70 |
| 136 | 1 | 1 | 6 | 1 | | | | | | 96 | |
| 145 | | | | | | 4-8 | | | | 100 | 100 |
| 149 | | | | | | | | | 85 | | |
| 162 | | | | | | | | | | 100 | 100 |
| 163 | 1 | 1 | 1 | 1 | 1 | 6 | 1 | 1 | | 90 | 90 |
| 186 | 0 | 0 | 0 | 0 | 0 | 8 | 2 | 0 | | 90 | 90 |
| 204 | 1 | 1 | 1 | 1 | 1 | 8 | 2 | 2 | | 85 | 95 |
| 206 | 1 | 1 | 1 | 1 | 1 | 6 | 1 | 1 | | 100 | 100 |
| 212 | | | | | | | | | 99 | 97 | 96 |
| 227 | | | | | | 8 | | | 90 | | |
| 235 | 6 | | 4 | | | | | | 50 | | |
| 243 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 90 | 90 | 80 |
| 268 | 1 | 1 | 1 | 1 | 1 | 4 | 1 | 1 | | 85 | 90 |
| 284 | 1 | 1 | 1 | 1 | 1 | 8 | 4 | 1 | | 100 | 95 |
| 311 | 1 | 1 | 1 | 1 | 1 | 8 | 4 | 1 | | 95 | 95 |
| 315 | 1 | 1 | 1 | 1 | 1 | 8 | 1 | 1 | | 80 | 80 |

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A02/2016 OS WB

DISPATCHED ON 02ND FEBRUARY 2016

HLA PHENOTYPE OF BLOOD DONOR: HLA-A11,A31; B7, B60; Cw7, Cw10; DR4, -; DQ7, DQ8

| | | | Summary of Results | | | | | | | | |
|--------------------------|-----------------------|-------------------|--------------------|-----------------|-----------------|---------------------|-----------------|-----------------|-----------------|---------------------|--------------------|
| | | | PBL/T-Cells | | | | B-Cells | | | | |
| Total tested | | | 17 | 16 | 17 | 16 | 15 | 15 | 15 | 15 | |
| Positive | | | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | |
| Negative | | | 16 | 16 | 17 | 16 | 15 | 14 | 15 | 15 | |
| NT/Equivocal | | | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | |
| % Positive | | | 5.9% | 0.0% | 0.0% | 0.0% | 0.0% | 6.7% | 0.0% | 0.0% | |
| % Negative | | | 94.1% | 100.0% | 100.0% | 100.0% | 100.0% | 93.3% | 100.0% | 100.0% | |
| Consensus | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |
| HLA Antibody Specificity | | | DR17+ | Cw4, Cw6 | B14+ | B8,B44,DR5,DR8 DR13 | DR17+ | Cw4, Cw6 | B14+ | B8,B44,DR5,DR8 DR13 | |
| (Defined By CDC) | | | With DTT | | | | With DTT | | | | |
| Lab No. | PBL/T Cell Assessment | B Cell Assessment | Serum 1 | Serum 2 | Serum 3 | Serum 4 | Serum 1 | Serum 2 | Serum 3 | Serum 4 | Comments |
| 101 | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |
| 114 | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |
| 116 | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |
| 133 | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |
| 149 | YES | NO | Negative | Negative | Negative | Negative | Negative | Positive | Negative | Negative | |
| 162 | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |
| 163 | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |
| 186 | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |
| 204 | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |
| 206 | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |
| 212 | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |
| 227 | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |
| 235 | YES | NO | Positive | NT | Negative | NT | | | | | Low cell viability |
| 268 | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |
| 284 | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |
| 311 | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |
| 315 | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A02/2016 OS WB

DISPATCHED ON 02ND FEBRUARY 2016

| Lab No. | PBL/T-cell with DTT | | | | B-cell with DTT | | | | Cell viability % | | |
|---------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|------------------|---------|---------|
| | Serum 1 reaction strength | Serum 2 reaction strength | Serum 3 reaction strength | Serum 4 reaction strength | Serum 1 reaction strength | Serum 2 reaction strength | Serum 3 reaction strength | Serum 4 reaction strength | PBL | T-cells | B-cells |
| 101 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | | 100 | 100 |
| 114 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | | | |
| 116 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | | 95 | 85 |
| 133 | 0 | 0 | 0 | 0 | 0 | ++++ | 0 | 0 | | 80 | 70 |
| 149 | | | | | | | | | 85 | | |
| 162 | | | | | | | | | | 100 | 100 |
| 163 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | | 90 | 90 |
| 186 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | | 90 | 90 |
| 204 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | | 85 | 95 |
| 206 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | | 100 | 100 |
| 212 | | | | | | | | | 99 | 97 | 96 |
| 227 | | | | | | | | | 90 | | |
| 235 | 6 | | 4 | | | | | | 50 | | |
| 268 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | | 85 | 90 |
| 284 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | | 100 | 95 |
| 311 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | | 95 | 95 |
| 315 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | | 80 | 80 |